GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impact BioMedical Inc (AMEX:IBO) » Definitions » Institutional Ownership

IBO (Impact BioMedical) Institutional Ownership : 0.77% (As of Apr. 16, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Impact BioMedical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Impact BioMedical's institutional ownership is 0.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Impact BioMedical's Insider Ownership is 0.85%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Impact BioMedical's Float Percentage Of Total Shares Outstanding is 55.38%.


Impact BioMedical Institutional Ownership Historical Data

The historical data trend for Impact BioMedical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impact BioMedical Institutional Ownership Chart

Impact BioMedical Historical Data

The historical data trend for Impact BioMedical can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.33 46.63 1.18 1.18 1.03 1.05 1.05 0.85

Impact BioMedical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Impact BioMedical Business Description

Traded in Other Exchanges
N/A
Address
275 Wiregrass Parkway, West Henrietta, NY, USA, 14586
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Impact BioMedical Headlines